Compare Abeona Therapeutics Inc (ABEO) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Marvell Technology Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Marvell Technology Inc trades at $231.78 (market cap $202.28B). The key difference: Marvell Technology Inc is far larger — about 541.8× Abeona Therapeutics Inc's market cap, and Marvell Technology Inc pays a 0.1% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MRVL | |
|---|---|---|
Market Cap | $373.32M | $202.28B |
Sector | Health | Technology |
52-Week High | $7.23 | $316.43 |
52-Week Low | $4.17 | $62.31 |
Enterprise Value | $228.22M | $203.71B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Marvell Technology (MRVL) trades at $230.7, down 5.95% amid a sector-wide chip stock selloff. The stock shows strong earnings beats in recent quarters but faces high valuation multiples with a P/E of 85.7 and P/S of 25.0. Technical indicators are neutral, with support near $234 and resistance at $257. Revenue growth is projected to surge to $8.7B in 2026, with net income turning positive to $2.5B, signaling a potential fundamental turnaround.
Outlook: MRVL's AI infrastructure growth and analyst consensus target of $262.6 offer upside, but high valuations and margin pressures pose risks. Investor sentiment is mixed due to semiconductor volatility, though institutional backing remains strong with 82% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
